Literature DB >> 8895537

Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer.

A G Zeimet1, C Natoli, M Herold, D Fuchs, G Windbichler, G Daxenbichler, S Iacobelli, O Dapunt, C Marth.   

Abstract

The tumor-associated antigen 90K is thought to play an important role in cellular immune defense against malignant cells. It is therefore of interest to investigate whether circulating 90K could be used as a prognostic variable in ovarian cancer, and whether this immunostimulatory antigen is related to other parameters known to be involved in the cellular immune response. In the present retrospective study, circulating levels of antigen 90K were measured before primary surgery in 152 ovarian-cancer patients. A very close association between antigen 90K and s-IL-2R concentrations was pointed out in a stepwise logistic regression model. Univariate analysis of overall survival revealed that antigen 90K and s-IL-2R were associated with poor prognosis. In the multivariate Cox regression, however, neither antigen 90K nor s-IL-2R retained independent prognostic significance. Urinary neopterin was shown to be the only independent prognostic variable among the "immunological parameters" investigated. Additionally, residual disease after primary tumor debulking and histopathologic tumor grade were the most prominent clinico-pathologic parameters for the independent prediction of poor clinical outcome in ovarian-cancer patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8895537     DOI: 10.1002/(SICI)1097-0215(19960927)68:1<34::AID-IJC7>3.0.CO;2-Y

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

1.  Spectral library-based glycopeptide analysis-detection of circulating galectin-3 binding protein in pancreatic cancer.

Authors:  Eslam N Nigjeh; Ru Chen; Yasuko Allen-Tamura; Randall E Brand; Teresa A Brentnall; Sheng Pan
Journal:  Proteomics Clin Appl       Date:  2017-07-10       Impact factor: 3.494

2.  Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Putative Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry (MRM-MS).

Authors:  Hyunsoo Kim; Su Jong Yu; Injun Yeo; Young Youn Cho; Dong Hyeon Lee; Yuri Cho; Eun Ju Cho; Jeong-Hoon Lee; Yoon Jun Kim; Sungyoung Lee; Jongsoo Jun; Taesung Park; Jung-Hwan Yoon; Youngsoo Kim
Journal:  Mol Cell Proteomics       Date:  2017-05-26       Impact factor: 5.911

3.  Development of glycoprotein capture-based label-free method for the high-throughput screening of differential glycoproteins in hepatocellular carcinoma.

Authors:  Rui Chen; Yexiong Tan; Min Wang; Fangjun Wang; Zhenzhen Yao; Liwei Dong; Mingliang Ye; Hongyang Wang; Hanfa Zou
Journal:  Mol Cell Proteomics       Date:  2011-04-07       Impact factor: 5.911

4.  High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer.

Authors:  A G Zeimet; M Widschwendter; M Uhl-Steidl; E Müller-Holzner; G Daxenbichler; C Marth; O Dapunt
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Identification of Mac-2-binding protein as a putative marker of neuroendocrine tumors from the analysis of cell line secretomes.

Authors:  Rajaventhan Srirajaskanthan; Martyn E Caplin; Mark G Waugh; Jennifer Watkins; Tim Meyer; J Justin Hsuan; Nicholas J Beaumont
Journal:  Mol Cell Proteomics       Date:  2009-12-17       Impact factor: 5.911

Review 6.  90K (Mac-2 BP) and galectins in tumor progression and metastasis.

Authors:  Antonino Grassadonia; Nicola Tinari; Ida Iurisci; Enza Piccolo; Alba Cumashi; Pasquale Innominato; Maurizia D'Egidio; Clara Natoli; Mauro Piantelli; Stefano Iacobelli
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

Review 7.  Biomarkers for malignant pleural mesothelioma: current status.

Authors:  Laurent Greillier; Paul Baas; John J Welch; Baktiar Hasan; Alexandre Passioukov
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

8.  Expression and significance of 90K/Mac-2BP in prostate cancer.

Authors:  Jianxin Hu; Jian He; Youlin Kuang; Zhenxing Wang; Zhaolin Sun; Hengcheng Zhu; Xiuheng Liu
Journal:  Exp Ther Med       Date:  2012-10-25       Impact factor: 2.447

9.  Cancer immunotherapy: potential involvement of mediators.

Authors:  S Ben-Efraim
Journal:  Mediators Inflamm       Date:  1997       Impact factor: 4.711

10.  Circulating autoantibodies to LGALS3BP: a novel biomarker for cancer.

Authors:  Antonino Grassadonia; Nicola Tinari; Clara Natoli; Galit Yahalom; Stefano Iacobelli
Journal:  Dis Markers       Date:  2013-11-18       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.